Arcus Biosciences (RCUS) Projected to Post Earnings on Tuesday

Arcus Biosciences (NYSE:RCUS - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect Arcus Biosciences to post earnings of ($1.02) per share and revenue of $38.61 million for the quarter.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($1.03) earnings per share for the quarter, topping the consensus estimate of ($1.17) by $0.14. The business had revenue of $36.00 million during the quarter, compared to the consensus estimate of $29.38 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. On average, analysts expect Arcus Biosciences to post $-3 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Arcus Biosciences Price Performance

Shares of NYSE:RCUS traded up $0.50 during trading on Friday, reaching $9.12. The company had a trading volume of 1,304,557 shares, compared to its average volume of 815,021. The firm's fifty day moving average is $8.58 and its 200 day moving average is $12.71. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. The firm has a market capitalization of $965.67 million, a PE ratio of -2.90 and a beta of 0.88. Arcus Biosciences has a twelve month low of $6.50 and a twelve month high of $18.98.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Bank of America decreased their price target on Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a research note on Wednesday, February 19th. HC Wainwright upgraded shares of Arcus Biosciences from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $18.00 to $24.00 in a research report on Wednesday, February 26th. Morgan Stanley reduced their price objective on shares of Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating for the company in a research report on Tuesday, February 18th. Finally, Barclays dropped their target price on shares of Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating on the stock in a report on Wednesday, April 23rd. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Arcus Biosciences currently has an average rating of "Buy" and a consensus price target of $28.38.

Insider Activity at Arcus Biosciences

In other news, Director Yasunori Kaneko acquired 20,000 shares of Arcus Biosciences stock in a transaction that occurred on Thursday, February 27th. The stock was purchased at an average price of $10.06 per share, with a total value of $201,200.00. Following the completion of the transaction, the director now owns 28,400 shares in the company, valued at approximately $285,704. This trade represents a 238.10 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Terry J. Rosen bought 19,800 shares of the company's stock in a transaction on Thursday, February 27th. The stock was purchased at an average cost of $10.18 per share, for a total transaction of $201,564.00. Following the completion of the transaction, the chief executive officer now owns 2,554,160 shares in the company, valued at approximately $26,001,348.80. The trade was a 0.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is owned by insiders.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.